MicroQuin

Executive Summary

MicroQuin is a Seattle-based biotechnology company pioneering a novel therapeutic approach by targeting the IntraCellular Environment (ICE). Founded in 2015, the company develops small molecules designed to rebalance cellular conditions disrupted by diseases such as cancer, viral infections, and neurodegenerative disorders. Its platform aims to selectively intervene in cellular regulatory mechanisms to slow, stop, or reverse disease progression. MicroQuin's unique focus on intracellular modulation differentiates it from traditional extracellular or ligand-based therapies, potentially enabling broad applicability across multiple disease areas. The company is privately held and has not disclosed funding details or valuation. Although early-stage, MicroQuin's platform holds promise for addressing high unmet medical needs, particularly in oncology and neurodegeneration, by targeting fundamental cellular processes. However, as a pre-commercial entity with limited public information, the risk profile is elevated, and significant milestones are required to validate the technology and advance toward clinical development.

Upcoming Catalysts (preview)

• TBDLead candidate IND filing20% success
• TBDSeries A financing round30% success
• TBDPreclinical proof-of-concept data in neurodegenerative disease model35% success